9 completed. 9 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 9 |
Follow migalastat: new trials by email Literature Review of migalastat trials Research Report on migalastat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study in Healthy Subjects to Investigate Whether Administration of Lucerastat Can Affect Normal Heart Function Lucerastat (Treatment A), Placebo, Moxifloxacin - Healthy | Phase 1 | Completed | Idorsia Pharmaceuticals Ltd. | 44 | 2019-02-14 | 2019-10-31 |
| Effect of Cimetidine on the Pharmacokinetics of Lucerastat in Healthy Subjects Lucerastat, Cimetidine - Healthy Subjects | Phase 1 | Completed | Idorsia Pharmaceuticals Ltd. | 14 | 2018-01-09 | 2022-06-02 |
| A Study to Assess the Safety and Tolerability of Lucerastat in Subjects With Fabry Disease Lucerastat, Enzyme replacement therapy (ERT) - Fabry Disease | Phase 1 | Completed | Idorsia Pharmaceuticals Ltd. | 14 | 2015-02-01 | 2018-07-10 |
| A Phase 1 Study To Evaluate the Safety of Migalastat Hydrochloride Given Intravenously to Healthy Volunteers IV migalastat HCl, IV placebo, oral migalastat HCl - Fabry Disease | Phase 1 | Completed | Amicus Therapeutics | 31 | 2014-03-01 | 2014-06-18 |
| Migalastat Food Effect Study A (migalastat), B (migalastat), C (migalastat) - Fabry Disease | Phase 1 | Completed | Amicus Therapeutics | 20 | 2011-10-01 | 2013-12-18 |
| A Phase I, Randomized, Single-Blind, Four-Period Cross-Over, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of GR181413A/AT1001 in Healthy Japanese Subjects GR181413A/AT1001 solution, GR181413A/AT1001 capsule, Potable water - Fabry Disease | Phase 1 | Completed | Amicus Therapeutics | 14 | 2011-09-01 | 2013-12-18 |
| Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function AT1001 150 mg - Fabry Disease | Phase 1 | Completed | Amicus Therapeutics | 32 | 2011-08-01 | 2017-08-03 |
| A Study to Assess the Safety, Tolerability and Pharmacokinetics of Lucerastat (CDP923) After Multiple Dosing in Healthy Subjects Lucerastat, Placebo - Healthy Subjects | Phase 1 | Completed | Idorsia Pharmaceuticals Ltd. | 37 | 2003-12-01 | 2025-05-02 |
| A Study to Assess the Safety and Pharmacokinetics of Lucerastat (OGT 923) in Healthy Subjects Lucerastat, Placebo - Healthy Subjects | Phase 1 | Completed | Idorsia Pharmaceuticals Ltd. | 39 | 2002-10-01 | 2025-05-01 |
Fabry Disease (5) · Lysosomal Storage Diseases (2)
Idorsia Pharmaceuticals Ltd. (5) · Amicus Therapeutics (4)
Germany (2) · Netherlands (2) · United Kingdom (2) · United States (2) · Australia (1)
PMID 28088251, PMID 27136905, PMID 27536442, PMID 31836927, PMID 33109218
2018 (1)